Icelandic scientists from Decode genetics have rare mutations in hectd2 and akap11 genes, which can increase the probability of development of bipolar disorder nine to a century. About it reported The company’s press service.
“Both of these DNA cross -sections are traditionally taken to the lithium funds used in the treatment of bipolar disorder, while another genome of the work is related to GSK3B. This can be used as a target for new drugs for new drugs for this disease.”
During the study, genetic analyzed the data of more than 4.2 thousand patients with bipolar disorder. The study also took into account information about 420 thousand healthy British and 1.8 thousand people who had such a diagnosis from British Biobank. The presence of rare mutations in Hectd2 and Akap11 genes increased the risk of developing the disease 9 and 11 times, respectively.
In these genes, mutations, which have not previously been associated with the disease, violate the activities of proteins and enzymes that regulate the activities of GSK3B. This discovery may lead to the creation of new therapeutic treatment methods completing traditional lithium -based treatment.
According to the World Health Organization, approximately 45 million people around the world suffer from bipolar disorder. The disease is accompanied by cyclic changes from mental mania (increasing mood and hyperactivity) to depression.
Previously, scientists open 60 -associated gene associated with congenital heart defects.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.